San Diego-based, late-stage pharmaceutical company focused on developing potential new therapies for cancer. Portfolio of drug candidates contains four clinical-stage candidates, including one candidate (zandelisib) in a Phase 2 clinical trial which they intend to submit to the U.S. Food and Drug administration to support an accelerated approval marketing application.